Voice Analysis Technology to Detect and Manage Depression and Anxiety in Cardiac Rehabilitation
Evaluation of Voice Analysis Technology in Detecting and Managing Depression and Anxiety in Patients Undergoing Cardiac Rehabilitation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Diana Albers
- Phone Number: (507) 255-6884
- Email: Albers.Diana2@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ≥ 18 years
- Enrolled in cardiac rehabilitation program to start within 3 months from hospital discharge
- Owns a smartphone
- Willing to download and use a smartphone app
- Able to read, write, and speak English
Exclusion Criteria:
- Cardiac transplant
- Active substance use
- Neurocognitive disorder
- Active psychosis
- Mania diagnosis
- Active suicidality
- Uncontrolled bipolar disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cardiac rehabilitation plus voice analysis
Subjects will complete 12 weeks of cardiac rehabilitation as per clinical care and utilize a voice analysis smartphone app.
|
Smartphone application that utilizes voice biomarkers to assess for potential presence and severity of depression and anxiety
|
|
No Intervention: Cardiac rehabilitation only
Subjects will complete 12 weeks of cardiac rehabilitation as per clinical care.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in depressive symptoms
Time Frame: Baseline, 12 weeks
|
Measured using the self-reported Patient Health Questionnaire-9 (PHQ-9) to assess for major depressive disorder.
Possible score range from 0 to 27, with higher scores indicating a worse outcome/greater severity of depressive symptoms.
|
Baseline, 12 weeks
|
|
Change in anxiety symptoms
Time Frame: Baseline, 12 weeks
|
Measured using the self-reported Generalized Anxiety Disorder 7-Item Scale (GAD-7) that assesses anxiety symptoms.
Possible score range from 0 to 21, with higher scores indicating a worse outcome/greater severity of anxiety symptoms.
|
Baseline, 12 weeks
|
|
Change in perceived stress
Time Frame: Baseline, 12 weeks
|
Measured using the self-reported Perceived Stress Scale-14 (PSS-14), a 14 item questionnaire which assesses the degree to which situations in life are stressful within the last month.
Each item is scored on a 5 point Likert scale from 0 (never) to 4 (very often), higher total scores indicate a worse outcome/greater severity of perceived stress.
|
Baseline, 12 weeks
|
|
Change in quality of life
Time Frame: Baseline, 12 weeks
|
Measured using the self-reported abbreviated generic Quality of Life Scale developed through the World Health Organization (WHOQOL-BREF) questionnaire that assesses an individual's perceptions of their health and well-being within the last two weeks.
Each item is scored on a 5 point Likert scale, higher scores indicate greater perceived quality of life.
|
Baseline, 12 weeks
|
|
Change in health behaviors
Time Frame: Baseline, 12 weeks
|
Measured using the self-reported Current Health Behaviors (HB) questionnaire, a 13 item questionnaire which assesses behaviors and life circumstances during the last month.
Each item is scored on a 10 point Likert scale, higher scores indicate better outcome.
|
Baseline, 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Virend Somers, MD, PhD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 21-012982
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.